Pharmacokinetic Characterization and Exposure-Response Relationship of Crovalimab in the COMPOSER and COMMODORE 3 Trials of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

医学 阵发性夜间血红蛋白尿 养生 伊库利珠单抗 药代动力学 加药 人口 药效学 内科学 临床试验 抗体 免疫学 补体系统 环境卫生
作者
Simon Buatois,Khaled Benkali,Andrea Henrich,Félix Jaminion,Yuchen Zhang,Alexandre Sostelly
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 2918-2920 被引量:5
标识
DOI:10.1182/blood-2022-158244
摘要

Background Crovalimab is a novel anti-human C5 monoclonal antibody being developed for the treatment of PNH, a rare, life-threatening, acquired hematopoietic stem cell disorder. Crovalimab is a next-generation C5 inhibitor that enables rapid and sustained C5 inhibition with subcutaneous (SC) self-administration every 4 weeks. COMPOSER (NCT03157635) is a 4-part open-label adaptive Phase I/II trial evaluating crovalimab in healthy volunteers and in patients with PNH who were treatment-naive or switched from eculizumab to crovalimab. COMMODORE 3 (NCT04654468) is a multicenter, single-arm, Phase III study evaluating crovalimab in treatment-naive patients with PNH in China. Crovalimab dosing and regimen were optimized in COMPOSER (Sostelly ASH 2019) and are currently being investigated in pivotal studies, including COMMODORE 3. The dose and regimen were: Week 1, Day 1: 1000 mg IV for body weight 40 to <100 kg or 1500 mg IV for weight ≥100 kgWeek 1, Day 2 and Weeks 2, 3, and 4: 340 mg SCWeek 5 onward: 680 mg SC for weight 40 to <100 kg or 1020 mg SC for weight ≥100 kg, Q4W The objectives were to characterize crovalimab's pharmacokinetics (PK) in healthy volunteers and treatment-naive patients with PNH, and to characterize the relationship between crovalimab's exposure parameters and pharmacodynamic (PD) biomarkers, efficacy, and safety, using data from COMPOSER and COMMODORE 3. Methods The legacy population PK model (Sostelly ASH 2019) was updated using data from healthy volunteers and treatment-naive patients from COMPOSER and COMMODORE 3 to characterize the crovalimab PK profile and evaluate impact of potential covariates. Simulations were conducted using the population PK model to evaluate the need for dose adjustment in the population based on the identified significant covariates. The relationships between crovalimab exposure and PD biomarkers, efficacy (normalized lactate dehydrogenase [LDH]), and safety endpoints were graphically explored. PD biomarkers included markers of terminal complement activity (50% hemolytic activity [CH50] as measured by liposome immunoassay [LIA]) and free C5. Safety endpoints included adverse events (AEs) of special interest, related serious AEs, related Grade ≥3 AEs, and any infections. Results Crovalimab PK was best described by a linear two-compartment model with first-order elimination and absorption. After SC administration, bioavailability was estimated to be 73.8% with a typical terminal half-life of 58.7 days (90% CI: 50.7, 74.1). Crovalimab clearances and volumes of distribution were allometrically scaled by body weight; patients with lower weight may experience relatively higher drug exposure vs those with higher weight. Age was found to be negatively correlated with the absorption rate constant without a clinically relevant impact on crovalimab exposure. The PK/PD relationship showed that crovalimab induced a concentration-dependent inhibition of terminal complement activity (Figure 1) and free C5 concentrations. Crovalimab concentrations above approximately 100 μg/mL resulted in inhibition of terminal complement activity as indicated by low CH50 values (LIA close or below the lower limit of quantification [10 U/mL]) and low free C5 (<0.0001 g/L in COMMODORE 3). No relationship was identified between observed steady-state crovalimab concentrations and LDH. For concentrations above approximately 100 μg/mL, no further LDH reduction could be achieved with higher concentrations. The recommended dosing regimen delivered adequate crovalimab concentration to achieve the desired LDH reduction. No relationship between crovalimab exposure and AE occurrence was identified, in line with other C5 inhibitors. Using the recommended dose and regimen, simulations of a representative treatment-naive patient population (based on patient characteristics across studies) showed that the predicted trough concentration at steady state remained above the threshold of 100 µg/mL in >95% of simulated patients (Figure 2). No dose adjustment was required for other intrinsic factors such as ethnicity, anti-drug antibody status, and hepatic or renal impairment. Conclusion PK characterization and exposure-response analyses supported the effectiveness and safety of the weight-based two-tiered crovalimab dosing approach for the treatment of adult and adolescent patients with PNH not currently treated with complement inhibitors. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
feiyang完成签到 ,获得积分0
1秒前
chen完成签到 ,获得积分10
2秒前
兴奋的天蓉完成签到 ,获得积分10
2秒前
愉快的友绿完成签到 ,获得积分10
3秒前
Xccc发布了新的文献求助10
4秒前
yang完成签到 ,获得积分10
5秒前
苗条的访冬完成签到 ,获得积分10
5秒前
英俊的铭的应助被活泼雪莲采纳,获得10
5秒前
卞卞完成签到,获得积分10
5秒前
趙途嘵生完成签到,获得积分10
7秒前
lyra1111完成签到,获得积分10
8秒前
12秒前
火星上的山河完成签到 ,获得积分10
13秒前
风趣的月光完成签到 ,获得积分10
14秒前
寒冷的映冬完成签到,获得积分10
14秒前
film完成签到 ,获得积分10
19秒前
arch完成签到,获得积分10
20秒前
酷炫大白完成签到,获得积分10
20秒前
兰先生完成签到,获得积分10
20秒前
欣喜烙完成签到 ,获得积分10
21秒前
21秒前
机智铭完成签到,获得积分10
22秒前
龙阿完成签到 ,获得积分10
23秒前
111完成签到,获得积分20
24秒前
小劳完成签到,获得积分10
25秒前
LIUJIE完成签到,获得积分10
25秒前
25秒前
活泼雪莲发布了新的文献求助10
25秒前
冬草完成签到,获得积分10
26秒前
情怀的应助被Benthesikyme采纳,获得10
26秒前
qaplay完成签到 ,获得积分0
26秒前
看文献完成签到,获得积分10
27秒前
chenying完成签到 ,获得积分0
31秒前
shuang完成签到,获得积分10
32秒前
32秒前
我就是KKKK完成签到,获得积分10
33秒前
gsxgg完成签到,获得积分10
35秒前
38秒前
快乐的小木虫完成签到,获得积分10
38秒前
csy完成签到,获得积分10
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923